Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2522937 | 0.91 | TSHR (0.61) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL15064928 | 0.89 | TSHR (0.53) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL2529508 | 0.84 | TSHR (0.56) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL5052712 | 0.81 | TSHR (0.56) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL15064565 | 0.80 | TSHR (0.55) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL197726 | 0.80 | TSHR (0.68) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL27357 | 0.80 | THRB (0.63) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL13046360 | 0.80 | TSHR (0.54) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL12793081 | 0.79 | TSHR (0.62) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL382201 | 0.79 | TSHR (0.61) | TSHRTHRBPOLBAPEX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8900297-B2 | Ophthalmic and otorhinolaryngological device materials | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-20140213733-A1 | Ophthalmic and Otorhinolaryngological Device Materials | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| US-8728157-B2 | Ophthalmic and otorhinolaryngological device materials | NOVARTIS AG (CH) | 2014-05-20 | — | — | US | disclosed |
| US-8163862-B2 | Ophthalmic and otorhinolaryngological device materials | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20110319992-A1 | OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE MATERIALS | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-8048154-B2 | Ophthalmic and otorhinolaryngological device materials | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20110257291-A1 | Ophthalmic and Otorhinolaryngological Device Materials | NOVARTIS AG (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20090093604-A1 | OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE MATERIALS | ALCON, INC. (CH) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257291-A1 | Ophthalmic and Otorhinolaryngological Device Materials | MYOC, MMS19, MSH2 | TSHR 1510/4885THRB 2951/4885POLB 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.